ES2637072T3 - Formulación parenteral de antibióticos macrólidos - Google Patents

Formulación parenteral de antibióticos macrólidos Download PDF

Info

Publication number
ES2637072T3
ES2637072T3 ES11754115.1T ES11754115T ES2637072T3 ES 2637072 T3 ES2637072 T3 ES 2637072T3 ES 11754115 T ES11754115 T ES 11754115T ES 2637072 T3 ES2637072 T3 ES 2637072T3
Authority
ES
Spain
Prior art keywords
composition
cem
pharmaceutical composition
agent
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11754115.1T
Other languages
English (en)
Spanish (es)
Inventor
David E. Pereira
Prabhavathi Fernandes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cempra Pharmaceuticals Inc
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2637072T3 publication Critical patent/ES2637072T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES11754115.1T 2010-03-10 2011-03-10 Formulación parenteral de antibióticos macrólidos Active ES2637072T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31241710P 2010-03-10 2010-03-10
US312417P 2010-03-10
PCT/US2011/027984 WO2011112864A1 (en) 2010-03-10 2011-03-10 Parenteral formulations of macrolide antibiotics

Publications (1)

Publication Number Publication Date
ES2637072T3 true ES2637072T3 (es) 2017-10-10

Family

ID=44563855

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11754115.1T Active ES2637072T3 (es) 2010-03-10 2011-03-10 Formulación parenteral de antibióticos macrólidos

Country Status (11)

Country Link
US (3) US20130045937A1 (enExample)
EP (1) EP2544537B1 (enExample)
JP (1) JP5890785B2 (enExample)
CN (2) CN102811616A (enExample)
AU (1) AU2011224238B2 (enExample)
CA (1) CA2792616A1 (enExample)
DK (1) DK2544537T3 (enExample)
ES (1) ES2637072T3 (enExample)
PL (1) PL2544537T3 (enExample)
SI (1) SI2544537T1 (enExample)
WO (1) WO2011112864A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638549A4 (en) 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
CA2703475A1 (en) 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US8796232B2 (en) 2008-10-24 2014-08-05 Cempra Pharmaceuticals, Inc. Methods for treating resistant diseases using triazole containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
JP5914335B2 (ja) 2009-09-10 2016-05-11 センプラ ファーマシューティカルズ,インコーポレイテッド マラリア、結核、及びmac病の治療方法
CN103080122A (zh) 2010-03-22 2013-05-01 森普拉制药公司 大环内脂的结晶形式及其用途
WO2011146829A1 (en) 2010-05-20 2011-11-24 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
JP6042334B2 (ja) 2010-09-10 2016-12-14 センプラ ファーマシューティカルズ,インコーポレイテッド 疾患治療のための水素結合形成フルオロケトライド
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun (Shanghai)Science & Technology Limited Compositions and methods for treating heart failure
CN104470527B (zh) * 2012-03-27 2019-05-28 森普拉制药公司 用于施用大环内酯抗生素的肠胃外制剂
RU2015138796A (ru) * 2013-03-14 2017-04-19 Семпра Фармасьютикалс, Инк. Способы и составы для лечения респираторных заболеваний
WO2014145210A1 (en) 2013-03-15 2014-09-18 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
JP6437523B2 (ja) 2013-04-04 2018-12-12 プレジデント アンド フェローズ オブ ハーバード カレッジ マクロライドならびにそれらの調製および使用の方法
EP2999499B1 (en) 2013-05-22 2019-07-17 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
BR112017002335A2 (pt) * 2014-08-05 2018-01-16 Cempra Pharmaceuticals, Inc. formulações de suspensão oral em pó de agentes antibacterianos
US10633407B2 (en) 2014-10-08 2020-04-28 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
EP3273969A4 (en) 2015-03-25 2018-11-21 President and Fellows of Harvard College Macrolides with modified desosamine sugars and uses thereof
WO2020264161A1 (en) * 2019-06-28 2020-12-30 Donald Picker Method of reconstituting liposomal annamycin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US20040019012A1 (en) * 2002-02-22 2004-01-29 Singh Satish K. Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
EP1638549A4 (en) * 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
CN101045063B (zh) * 2006-03-28 2011-01-26 广州朗圣药业有限公司 注射用克拉霉素水溶性制剂
CN101129383B (zh) * 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方

Also Published As

Publication number Publication date
CN109091489A (zh) 2018-12-28
EP2544537A4 (en) 2014-05-14
CA2792616A1 (en) 2011-09-15
JP5890785B2 (ja) 2016-03-22
EP2544537A1 (en) 2013-01-16
JP2013522229A (ja) 2013-06-13
AU2011224238B2 (en) 2015-11-26
CN102811616A (zh) 2012-12-05
US20190054059A1 (en) 2019-02-21
US20130045937A1 (en) 2013-02-21
US20200276150A1 (en) 2020-09-03
PL2544537T3 (pl) 2017-10-31
EP2544537B1 (en) 2017-05-10
DK2544537T3 (en) 2017-08-28
WO2011112864A1 (en) 2011-09-15
AU2011224238A1 (en) 2012-10-04
SI2544537T1 (sl) 2017-12-29

Similar Documents

Publication Publication Date Title
DK2544537T3 (en) PARENTERAL FORMULATIONS OF MACROLIDE ANTIBIOTICS
US10188674B2 (en) Parenteral formulations for administering macrolide antibiotics
ES2608285T3 (es) Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC
ES2384451T3 (es) Aplicación de levo-ornidazol en la preparación de un medicamento contra la infección de bacterias anaeróbicas .
ES2356242T3 (es) Preparación liofilizada conteniendo metilcobalamina y procedimiento de producción de esta preparación.
EA022765B1 (ru) Фармацевтическая композиция
EP2303228B1 (en) Fosphenytoin composition
ES2862209T3 (es) Composiciones orales sólidas de liberación prolongada no pulsátil que contienen betahistina
HK40002820A (en) Parenteral formulations of macrolide antibiotics
HK1179115A (en) Parenteral formulations of macrolide antibiotics
ES2346573T3 (es) Composiciones de cefquinoma y metodos para su uso.
HK1180184B (en) Parenteral formulations of macrolide antibiotics
HK1180184A (en) Parenteral formulations of macrolide antibiotics
KR20160090312A (ko) 조산 조건의 치료에서 사용을 위한 용량 단위의 조합
BR112019017223A2 (pt) macrolídeos contendo triazol e seus usos oftálmicos
HK1208622B (zh) 用於施用大环内酯抗生素的肠胃外制剂